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263. BIOMARKERS IN OVARIAN CANCER
Rahela Manoli
Scientific adviser: Silvia Stratulat, Associate Professor, Departament of Biochemistry and clinical 
Biochemistry, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of 
Moldova
Introduction: Elucidation of the most frequent biomarkers in ovarian cancer.
Materials and methods: The study was based on the analysis of biographical sources from 2007-
2014.
Discussion results: One of the major challenges in cancer research is the identification of stable 
biomarkers, which can be routinely measured noninvasively in easily accessible samples. Ovarian cancer 
is one such disease that would benefit from improved diagnostic markers. Ovarian cancer is the leading 
cause of death from gynecological malignancy in the western world. One way to facilitate early detection 
of ovarian cancer is through screening, but currently available diagnostic tools, including ovarian cancer 
biomarkers and clinical imaging, lack sufficient specificity and sensitivity for implementation in a 
population-based screening program.
Conclusions: The ability to sensitively and specifically predict the presence of early disease and 
its status, stage and Associated therapeutic efficacy has the potential to revolutionize ovarian cancer 
detection and treatment and to greatly improve the quality of life and survival rates of ovarian cancer 
patients.
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264. THE ROLE OF GLUTATHIONE IN CANCER DEVELOPMENT AND 
CHEMORESISTANCE
Daniela Mirzac
Scientific adviser: Tatiana Timercan, University Assistant, Department of Biochemistry and Clinical 
Biochemistry, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of 
Moldova
Introduction: Glutathione (GSH) is a tripeptide produced by the liver and has the ability (among 
others) to remove a wide range of toxins, including those produced by heavy metals, alcohol, smoking, 
radiation and cancer chemotherapy. Elevated GSH levels were detected in various types of tumors, along
with high levels of GSH-related enzymes, such as -glutamylcysteine ligase (GCL) and -glutamyl-
transpeptidase (GGT), GSH-transporting export pumps. This makes the neoplastic tissues more resistant 
to chemotherapy. Therefore, the GSH system attracted the attention of scientists as a possible target for 
medical intervention against cancer progression and chemoresistance.
Materials and methods: The presentation represents an extensive literature review and is based 
on relevant scientific articles regarding the subject from medical databases.
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Discussion results: The main research in the field aimed at depleting GSH by a specific 
inhibition of GCL, a key enzyme of GSH biosynthesis. But GSH depletion appears to be therapeutically 
effective when very low levels (<10% of their control values) can be achieved within the cancer cells. 
Thus, achievement of selective tumor GSH depletion under in vivo circumstances is a pharmacological 
challenge. Also, GSH synthesis and GSH synthesis-linked genes are up-regulated during oxidative stress 
and inflammation. Furthermore, Nrf-2 deficient cells were more susceptible to doxorubicin and BSO 
treatment-induced cell death than wild cells. Moreover, propyl gallate activated caspases 3, 8, and 9, and 
induced an increase in p53, Bax, Fas, and Fas Ligand; whereas MAPKs inhibited nuclear translocation 
of Nrf-2 and induced intracellular GSH depletion in human leukemia. This indicates that Nrf-2 is one of 
the first factors that induce cell survival under GSH depletion, which points out to this transcription 
factor as an attractive target in leukemia but also in other cancers sharing similar molecular mechanisms. 
The increase in GSH is a major contributing factor to drug resistance by binding to or reacting with, 
drugs, interacting with ROS, preventing damage to proteins or DNA, or by participating in DNA repair 
processes.
Conclusion: The modulation of cellular GSH is a double-edged sword. On one hand, enhancing 
the capacity of GSH and its Associated enzymes represents an aim in the search for cytoprotective 
strategies against cancer. On the other hand, the strategy of depleting GSH and GSH-related 
detoxification pathways is aimed at sensitizing cancer cells to chemotherapy. Keywords: Glutathione, 
cancer development, chemoresistance.
265. TUFTSIN-BIOLOGICAL ROLE AND PHARMACEUTICAL VALUE
Varvara Naghita
Scientific adviser: Catcov Carolina, PhD, Department of Pharmacology and Clinical Pharmacology, 
Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
Introduction: Despite the high level the human civilization achieved, we still constantly face 
dangers as viral infections, bacteria, traumas, chronic disease, cancer etc. Thanks to the development of 
medicine and pharmaceutics, antibiotics, anti-inflammatory and immunomodulatory drugs as well as 
cytostatic and cancer killing drugs were developed. Still, many of them have many adverse reactions, or 
are expensive, or both. That is why the discovery of Tuftsin in 1970 is considered one of a high value 
for the modern medicine, by offering new ways of treatment of the diseases, which endanger health and 
life.
Objectives and Purposes of this work was to identify the immunomodulatory, anti-
inflammatory, antibacterial and cancer killing properties of Tuftsin.
Materials and Methods: A bibliographic review of the scientific articles published over the 
studies of Tuftsin and its properties, during 1980-2012, was performed. 
Results: In 1970s, Victor A. Najjar and Kenji Nishioka found a new natural tetrapeptide (Thr-
Lys-Pro-Arg) derived from the proteolytic degradation of the 289–292 amino acid residues of the IgG 
heavy chain Fc domain that was named tuftsin. Tuftsin is produced by the action of two proteolytic 
enzymes – splenic tuftsin edocarboxypeptidase and leukokininase. 
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